- Conditions
- Mammographically Dense Breast
- Interventions
- Afimoxifene, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 40 Years to 69 Years · Female only
- Enrollment
- 194 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Tampa, Florida • Chicago, Illinois • Boston, Massachusetts + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Cancer Survivor, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma
- Interventions
- Afimoxifene, Core Biopsy, Questionnaire Administration
- Drug · Procedure · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Breast Cancer
- Interventions
- 4-hydroxytamoxifen, breast imaging study, radiomammography
- Drug · Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 30 Years to 50 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Breast Atypical Hyperplasia, Breast Lobular Carcinoma in Situ, Breast Atypical Lobular Hyperplasia, Breast Carcinoma
- Interventions
- Tamoxifen, Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day, Placebo, Questionnaire Administration
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Evanston, Illinois • Rochester, Minnesota • Camden, New Jersey
- Conditions
- Ductal Breast Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer
- Interventions
- oral placebo, afimoxifene, tamoxifen citrate, placebo gel
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Mammographic Breast Density
- Interventions
- 4-OH tamoxifen, Placebo
- Drug
- Lead sponsor
- BHR Pharma, LLC
- Industry
- Eligibility
- 35 Years to 75 Years · Female only
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 17
- States / cities
- Mesa, Arizona • Tucson, Arizona • Beverly Hills, California + 14 more
- Conditions
- Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive
- Interventions
- Afimoxifene, Laboratory Biomarker Analysis, Placebo, Tamoxifen Citrate
- Drug · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Edgewood, Kentucky • Rochester, Minnesota + 3 more